Trials / Completed
CompletedNCT00343577
Antiproteinuric Agents and Fabry Disease
Observational Study of Antiproteinuric Agents in Patients With Fabry Disease Treated With Enzyme Replacement Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12 (planned)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 14 Years – 95 Years
- Healthy volunteers
- Not accepted
Summary
Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion. Proteinuria is recognized as an important risk factor for progression of chronic kidney disease. Our hypothesis is that using drugs that reduce urine protein excretion (ACE inhibitors and ARBs) will have a beneficial effect on patients with Fabry disease who already are receiving enzyme replacement therapy. A longitudinal, observational study is being undertaken to determine the utility of these agents in Fabry disease, realizing that these agents are primarily indicated for reducing systemic blood pressure, and most patients with Fabry disease have relatively low blood pressures at baseline.
Detailed description
Fabry disease is a rare disorder that often has kidney involvement with increased urine protein excretion. Proteinuria is recognized as an important risk factor for progression of chronic kidney disease. Our hypothesis is that using drugs that reduce urine protein excretion (ACE inhibitors and ARBs) will have a beneficial effect on patients with Fabry disease who already are receiving enzyme replacement therapy. A longitudinal, observational study is being undertaken to determine the utility of these agents in Fabry disease, realizing that these agents are primarily indicated for reducing systemic blood pressure, and most patients with Fabry disease have relatively low blood pressures at baseline.
Conditions
Timeline
- Start date
- 2001-01-01
- Completion
- 2006-12-01
- First posted
- 2006-06-23
- Last updated
- 2013-11-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00343577. Inclusion in this directory is not an endorsement.